Company: NIVFW
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001213900-25-104469
Chunk: 77

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-31
Form: 424B3
Chunk 77
---
failure to renew such contracts could have a material adverse effect on its business and results of operations. Adoption of new laws,
rules or regulations or changes in, or new interpretations of, existing laws, rules or regulations, relating to any of these programs
could materially adversely affect its business and results of operations.

NewGenIvf has engaged in transactions with related parties, and such transactions present potential conflicts of interest that could have an adverse effect on its business and results of operations.

NewGenIvf has entered into
a number of transactions with related parties. NewGenIvf may in the future enter into additional transactions with its related parties.
Interests of these related parties may not necessarily be aligned with NewGenIvf’s or The Company’s interests and the interests
of its other shareholders. For example, conflicts of interest may arise in connection with decisions regarding the transaction arrangements
which may be less favorable to NewGenIvf than similar arrangements negotiated with unaffiliated third parties. Conflicts of interest
may also arise in connection with the exercise of contractual remedies, such as the treatment of events of default. As a result, those
related party transactions, individually or in the aggregate, may have an adverse effect on NewGenIvf’s business and results of
operations.

<div align='center'>43</div>

NewGenIvf may be subject to claims and allegations relating to intellectual property and other causes.

NewGenIvf may from time to
time receive claims that NewGenIvf infringes on the intellectual property rights of others. Moreover, NewGenIvf may be subject to claims
by third parties who maintain that NewGenIvf’s service providers’ technology infringes third-party’s intellectual property
rights. If NewGenIvf fails to successfully defend against such claim or does not prevail in such litigation, it could be required to
modify, redesign or cease operating, pay monetary amounts as damages or enter into royalty or licensing arrangements with the valid intellectual
property holders. Any royalty or licensing arrangements that NewGenIvf may seek in such circumstances may not be available to it on commercially
reasonable terms or at all. Also, if NewGenIvf acquires technology licenses from third parties, NewGenIvf’s exposure to infringement
actions may increase because NewGenIvf must rely upon these third parties to verify the origin and ownership of such technology. This
exposure to liability could result in disruptions in NewGenIvf’s business that could materially and adversely affect NewGenIvf’s
results of operations